A number of studies have shown consistently the loss of imprint of IGF-2, which are associated with increased risk of several cancers, including those cutaneous melanoma, laryngeal squamous cell carcinoma, human meningiomas and breast cancer [24]–[26]. This evidence concerns the gene IGF2 and breast carcinoma.